Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease

Publication | Closed Access

DOI

Citations

References

1999

Year

DE Reece, TJ Nevill, Antoine Sayegh, JJ Spinelli, DA Brockington, MJ Barnett, H-G Klingemann, JM Connors, S.H. Nantel, JD Shepherd,

Bone Marrow Transplantation

Non-relapse MortalityCell TherapyTransplantationHigh-dose CyclophosphamideMedicineImmunodeficienciesStem Cell TransplantationHematologyTherapeutic EfficacyRadiation OncologyOncologyCell TransplantationRegimen-related ToxicityHealth Sciences